Primary Diffuse Large B-Cell Lymphoma of the CNS · line 1 · MATRix (HD-Methotrexate + HD-Cytarabine + Thiotepa + Rituximab), 4 cycles
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-MATRIX |
| ID | IND-PCNSL-1L-MATRIX |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-PCNSL |
| Sources | SRC-NCCN-BCELL-2025 SRC-NCCN-CNS-2025 |
Notes
STUB. Тіотепа в Україні може бути обмежена — fall back на R-MPV. HD-MTX потребує hospital admission з мониторингом MTX levels кожні 24h.
Used By
Algorithms
ALGO-PCNSL-1L- ALGO-PCNSL-1L
Contraindications
CI-RENAL-FAILURE-FOR-HD-MTX- CI-RENAL-FAILURE-FOR-HD-MTX